Literature DB >> 28376298

Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability.

Alexander M Sherwood1, Rachel Saylor Crowley1, Kelly F Paton2, Andrew Biggerstaff2, Benjamin Neuenswander1, Victor W Day3, Bronwyn M Kivell2, Thomas E Prisinzano1.   

Abstract

Previous structure-activity studies on the neoclerodane diterpenoid salvinorin A have demonstrated the importance of the acetoxy functionality on the A-ring in its activity as a κ-opioid receptor agonist. Few studies have focused on understanding the role of conformation in these interactions. Herein we describe the synthesis and evaluation of both flexible and conformationally restricted compounds derived from salvinorin A. One such compound, spirobutyrolactone 14, was synthesized in a single step from salvinorin B and had similar potency and selectivity to salvinorin A (EC50 = 0.6 ± 0.2 nM at κ; >10000 nM at μ and δ). Microsomal stability studies demonstrated that 14 was more metabolically resistant than salvinorin A. Evaluation of analgesic and anti-inflammatory properties revealed similar in vivo effects between 14 and salvinorin A. To our knowledge, this study represents the first example of bioisosteric replacement of an acetate group by a spirobutyrolactone to produce a metabolically resistant derivative.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28376298      PMCID: PMC5546011          DOI: 10.1021/acs.jmedchem.7b00148

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  53 in total

1.  Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone.

Authors:  Yan Zhou; Rachel Saylor Crowley; Konrad Ben; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  Brain Res       Date:  2017-03-02       Impact factor: 3.252

Review 2.  Current developments in the discovery and design of new drug candidates from plant natural product leads.

Authors:  Kuo-Hsiung Lee
Journal:  J Nat Prod       Date:  2004-02       Impact factor: 4.050

Review 3.  Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources.

Authors:  Will C McClatchey; Gail B Mahady; Bradley C Bennett; Laura Shiels; Valentina Savo
Journal:  Pharmacol Ther       Date:  2009-05-05       Impact factor: 12.310

4.  A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics.

Authors:  André Cruz; Sara Domingos; Eugenia Gallardo; Ana Martinho
Journal:  Phytochemistry       Date:  2017-02-10       Impact factor: 4.072

5.  Treatment of cocaine craving with as-needed nalmefene, a partial κ opioid receptor agonist: first clinical experience.

Authors:  Martin Grosshans; Jochen Mutschler; Falk Kiefer
Journal:  Int Clin Psychopharmacol       Date:  2015-07       Impact factor: 1.659

6.  Molecular field technology applied to virtual screening and finding the bioactive conformation.

Authors:  Tim Cheeseright; Mark Mackey Phd; Sally Rose Phd; Andy Vinter Phd
Journal:  Expert Opin Drug Discov       Date:  2007-01       Impact factor: 6.098

7.  Identification of novel functionally selective κ-opioid receptor scaffolds.

Authors:  Kate L White; Alex P Scopton; Marie-Laure Rives; Ruslan V Bikbulatov; Prabhakar R Polepally; Peter J Brown; Terrance Kenakin; Jonathan A Javitch; Jordan K Zjawiony; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2013-10-10       Impact factor: 4.436

8.  Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist.

Authors:  Thomas A Munro; Mark A Rizzacasa; Bryan L Roth; Beth A Toth; Feng Yan
Journal:  J Med Chem       Date:  2005-01-27       Impact factor: 7.446

9.  Ruthenium-catalyzed hydrohydroxyalkylation of acrylates with diols and α-hydroxycarbonyl compounds to form spiro- and α-methylene-γ-butyrolactones.

Authors:  Emma L McInturff; Jeffrey Mowat; Andrew R Waldeck; Michael J Krische
Journal:  J Am Chem Soc       Date:  2013-11-05       Impact factor: 15.419

10.  Discovery of Small Molecules that Inhibit the Disordered Protein, p27(Kip1).

Authors:  Luigi I Iconaru; David Ban; Kavitha Bharatham; Arvind Ramanathan; Weixing Zhang; Anang A Shelat; Jian Zuo; Richard W Kriwacki
Journal:  Sci Rep       Date:  2015-10-28       Impact factor: 4.379

View more
  10 in total

1.  Semisynthesis and Kappa-Opioid Receptor Activity of Derivatives of Columbin, a Furanolactone Diterpene.

Authors:  Anil Yilmaz; Rachel Saylor Crowley; Alexander M Sherwood; Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2017-07-18       Impact factor: 4.050

Review 2.  Natural Products in the "Marketplace": Interfacing Synthesis and Biology.

Authors:  Benjamin J Huffman; Ryan A Shenvi
Journal:  J Am Chem Soc       Date:  2019-02-13       Impact factor: 15.419

3.  Modular Approach to pseudo-Neoclerodanes as Designer κ-Opioid Ligands.

Authors:  Alexander M Sherwood; Samuel E Williamson; Rachel S Crowley; Logan M Abbott; Victor W Day; Thomas E Prisinzano
Journal:  Org Lett       Date:  2017-09-14       Impact factor: 6.005

4.  The quest for supernatural products: the impact of total synthesis in complex natural products medicinal chemistry.

Authors:  Zhi-Chen Wu; Dale L Boger
Journal:  Nat Prod Rep       Date:  2020-11-10       Impact factor: 13.423

Review 5.  A review of salvinorin analogs and their kappa-opioid receptor activity.

Authors:  Jeremy J Roach; Ryan A Shenvi
Journal:  Bioorg Med Chem Lett       Date:  2018-03-12       Impact factor: 2.823

Review 6.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

Review 7.  Chemical syntheses of the salvinorin chemotype of KOR agonist.

Authors:  Sarah J Hill; Aurélien U C M Brion; Ryan A Shenvi
Journal:  Nat Prod Rep       Date:  2020-11-18       Impact factor: 13.423

8.  Dynamic Strategic Bond Analysis Yields a Ten-Step Synthesis of 20-nor-Salvinorin A, a Potent κ-OR Agonist.

Authors:  Jeremy J Roach; Yusuke Sasano; Cullen L Schmid; Saheem Zaidi; Vsevolod Katritch; Raymond C Stevens; Laura M Bohn; Ryan A Shenvi
Journal:  ACS Cent Sci       Date:  2017-12-13       Impact factor: 14.553

9.  Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents.

Authors:  Bronwyn M Kivell; Kelly F Paton; Nitin Kumar; Aashish S Morani; Aimee Culverhouse; Amy Shepherd; Susan A Welsh; Andrew Biggerstaff; Rachel S Crowley; Thomas E Prisinzano
Journal:  Molecules       Date:  2018-10-11       Impact factor: 4.411

Review 10.  Natural Products for the Treatment of Pain: Chemistry and Pharmacology of Salvinorin A, Mitragynine, and Collybolide.

Authors:  Soumen Chakraborty; Susruta Majumdar
Journal:  Biochemistry       Date:  2020-09-22       Impact factor: 3.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.